Biomedical Research Institute

Theriva™ Biologics Reports Second Quarter 2023 Operational Highlights and Financial Results

Retrieved on: 
Tuesday, August 8, 2023

ET -

Key Points: 
  • ET -
    ROCKVILLE, Md., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results for the second quarter ended June 30, 2023, and provided a corporate update.
  • These results build on the impressive safety, biochemical and mechanistic data presented last year, demonstrating that VCN-01 improved tumor immunogenicity in previously immunotherapy refractory patients.
  • Second Quarter Ended June 30, 2023 Financial Results
    General and administrative expenses increased to $2.7 million for the three months ended June 30, 2023, from $1.5 million for the three months ended June 30, 2022.
  • ET to discuss its financial results for the quarter ended June 30, 2023 and provide a corporate update.

Theriva Biologics Announces Appointment of Ramon Alemany, Ph.D., to Senior Vice President of Discovery

Retrieved on: 
Tuesday, May 23, 2023

ROCKVILLE, Md., May 23, 2023 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced the appointment of Dr. Ramon Alemany as Senior Vice President of Discovery, effective immediately. Dr. Alemany will oversee Theriva’s discovery and development pipeline and will continue to serve as Chair of the Scientific Advisory Board.

Key Points: 
  • ROCKVILLE, Md., May 23, 2023 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced the appointment of Dr. Ramon Alemany as Senior Vice President of Discovery, effective immediately.
  • Dr. Alemany will oversee Theriva’s discovery and development pipeline and will continue to serve as Chair of the Scientific Advisory Board.
  • “Ramon is an internationally recognized expert in oncolytic adenoviruses and as Co-Founder of VCN Biosciences, is uniquely suited to lead Theriva’s discovery program through its next critical phase of development,” said Steven A. Shallcross, Chief Executive Officer of Theriva Biologics.
  • Combining novel viral payloads with the proprietary Albumin Shield technology to protect systemically administered oncolytic viruses from the host immune system has tremendous potential for our pipeline.”

SNU Bundang Hospital and Cipherome, Inc. conclude an MOU for cooperation in Personalized Medicine

Retrieved on: 
Wednesday, November 16, 2022

Seoul National University (SNU) Bundang Hospital Biomedical Research Institute announced that it concluded the MOU on November 15, 2022, to standardize clinico genomic research using Cipherome, Inc.s precision medicine research platform at Precision Medicine Center.

Key Points: 
  • Seoul National University (SNU) Bundang Hospital Biomedical Research Institute announced that it concluded the MOU on November 15, 2022, to standardize clinico genomic research using Cipherome, Inc.s precision medicine research platform at Precision Medicine Center.
  • View the full release here: https://www.businesswire.com/news/home/20221116006039/en/
    Seoul National University Bundang Hospital Biomedical Research Institute signed a memorandum of understanding (MOU) with Cipherome, Inc., a precision medicine bio venture company based in Silicon Valley, USA, to build a precision medicine research platform.
  • Ji-Soo Kim, the president of Seoul National University Bundang Hospital Biomedical Research Institute, stated: Through this MOU with Cipherome, we will actively support the precision medicine R&D based on clinical and genomic big data.
  • We hope that this MOU will contribute to improving the precision medicine research competitiveness and capability of Seoul National University Bundang Hospital.

LA County Board of Supervisors Approves Plan For 15-Acre Biosciences Technology Park at The Lundquist Institute

Retrieved on: 
Wednesday, November 18, 2020

The Lundquist Institute received unanimous approval from the Los Angeles County Board of Supervisors to begin development of a 15-acre biotech park, which will serve as a hub and catalyst for the regions rapidly-developing bioscience industry.

Key Points: 
  • The Lundquist Institute received unanimous approval from the Los Angeles County Board of Supervisors to begin development of a 15-acre biotech park, which will serve as a hub and catalyst for the regions rapidly-developing bioscience industry.
  • In the first phase of the master plan, The Lundquist Institute will oversee the construction of three buildings totaling up to 250,000 square feet, with top-of-the-line laboratory, manufacturing and office space.
  • Last year, the institute opened an incubator, BioLabs at The Lundquist Institute, which is now home to more than 20 early-stage startups.
  • The Lundquist Institute, formerly the Los Angeles Biomedical Research Institute (LA BioMed), is an engine of innovation with a global reach and a 68-year reputation of improving and saving lives.

NIH-Sponsored COVID-19 Clinical Trial Begins at The Lundquist Institute

Retrieved on: 
Thursday, May 7, 2020

The Lundquist Institute has delivered life-saving innovations for decades, and we are pleased to be selected as one of the sites for this crucial trial, said David Meyer, PhD, President and CEO of The Lundquist Institute.

Key Points: 
  • The Lundquist Institute has delivered life-saving innovations for decades, and we are pleased to be selected as one of the sites for this crucial trial, said David Meyer, PhD, President and CEO of The Lundquist Institute.
  • During the trial, patients will receive seven days of treatment with drugs or placebo, with a follow-up appointment at 20 days.
  • The Lundquist Institute, with its extensive background and history in clinical studies on viruses, such as HIV, is ideally prepared to hit the ground running in this study.
  • The Lundquist Institute, formerly the Los Angeles Biomedical Research Institute (LA BioMed), is an engine of innovation with a global reach and a 67-year reputation of improving and saving lives.

Institute for Women’s and Children’s Health Launched at The Lundquist Institute

Retrieved on: 
Thursday, March 5, 2020

Today, The Lundquist Institute, formerly known as the Los Angeles Biomedical Research Institute (LA BioMed), located at Harbor-UCLA Medical Center, held the inaugural meeting of its Institute for Womens and Childrens Health (IWCH).

Key Points: 
  • Today, The Lundquist Institute, formerly known as the Los Angeles Biomedical Research Institute (LA BioMed), located at Harbor-UCLA Medical Center, held the inaugural meeting of its Institute for Womens and Childrens Health (IWCH).
  • Mina Desai, Virender Rehan and Michael Rosseach noted for his or her experience and expertise in a variety of issues facing womens and childrens health.
  • And in 1995, Dr. Iraj Khalkhali achieved advances in noninvasive detection of breast cancer at The Lundquist Institute.
  • The opening of IWCH is just the latest milestone in The Lundquist Institutes long legacy of advancing women and childrens health, which has been a significant priority for The Lundquist Institute.

BioLabs LA at The Lundquist Institute Announces 3 New Startup Companies

Retrieved on: 
Wednesday, February 19, 2020

Vangenes launches its U.S. arm at BioLabs LA with the goal of making NIPPT more accessible globally.

Key Points: 
  • Vangenes launches its U.S. arm at BioLabs LA with the goal of making NIPPT more accessible globally.
  • "We chose this environment because BioLabs LA and its members share a long-term vision and passion for discovering and solving complex issues related to life sciences.
  • The acceptance of these three startups within BioLabs LA at The Lundquist Institute highlights the latest innovators that are furthering the next advancements in genomics and, less than a year after breaking ground, marks a total of 13 companies that now call BioLabs LA home.
  • The Lundquist Institute, formerly the Los Angeles Biomedical Research Institute (LA BioMed), is an engine of innovation with a global reach and a 67-year reputation of improving and saving lives.

The Lundquist Institute Promotes Jody Spillane to Senior Vice President of Public Affairs

Retrieved on: 
Thursday, December 19, 2019

The Lundquist Institute, formerly the Los Angeles Biomedical Research Institute (LA BioMed), has promoted Jody Spillane to Senior Vice President of Public Affairs.

Key Points: 
  • The Lundquist Institute, formerly the Los Angeles Biomedical Research Institute (LA BioMed), has promoted Jody Spillane to Senior Vice President of Public Affairs.
  • View the full release here: https://www.businesswire.com/news/home/20191219005210/en/
    The Lundquist Institute Promotes Jody Spillane to Senior Vice President of Public Affairs (Photo: Business Wire)
    In her new and expanded role, Spillane will oversee the institutes communications strategy in addition to assisting in government relations efforts and leading the organizations education and training efforts.
  • In her new role she will work closely with community stakeholders, public officials and the news media to advance The Lundquist Institutes mission.
  • Previously, as Vice President for Education and Executive Communications at the Lundquist Institute, Spillane was instrumental in launching the institutes first doctoral program in translational biomedical research, the first comprehensive degree of its kind.

LA BioMed Becomes the Lundquist Institute, Debuts New Logo and Tagline

Retrieved on: 
Tuesday, September 10, 2019

The Lundquist Institute also has a new logo and a new tagline: Research with Reach.

Key Points: 
  • The Lundquist Institute also has a new logo and a new tagline: Research with Reach.
  • "The Lundquist Institute is working to benefit all citizens of the world, developing diagnostics, devices, and therapies that transform today's research into tomorrow's cures," said Richard Lundquist.
  • "We are honored to see LA BioMed transformed into the Lundquist Institute in recognition of the phenomenal support the Lundquists have given our campus over the years," said David Meyer, PhD, President and CEO, the Lundquist Institute.
  • The Lundquist Institute, formerly the Los Angeles Biomedical Research Institute (LA BioMed), is an engine of innovation with a global reach and a 67-year reputation of improving and saving lives.

LA BioMed recruits Chronicle of Philanthropy Superstar as New Vice President for Development

Retrieved on: 
Tuesday, May 8, 2018

LOS ANGELES, May 8, 2018 /PRNewswire/ --To elevate its fundraising progress, LA BioMed CEO David Meyer announced the addition of Ernie Iseminger as the new Vice President of Development at The Los Angeles Biomedical Research Institute (LA BioMed).

Key Points: 
  • LOS ANGELES, May 8, 2018 /PRNewswire/ --To elevate its fundraising progress, LA BioMed CEO David Meyer announced the addition of Ernie Iseminger as the new Vice President of Development at The Los Angeles Biomedical Research Institute (LA BioMed).
  • "Ernie will be integral to LA BioMed's next growth stage," said David Meyer, PhD, LA BioMed President and CEO.
  • Iseminger joins LA BioMed from the Claremont Graduate University, where, as a member of the Senior Cabinet he held the position of Vice President for Advancement, and oversaw Development, Marketing, Communications and Alumni Engagement.
  • LA BioMed is an incubator of innovation with a global reach and a 66-year reputation of changing and saving lives.